{"title":"慢性淋巴细胞白血病患者口服氟达拉滨后的急性肿瘤溶解综合征。","authors":"Akila Ramachandran, Gautam Majumdar","doi":"10.1038/sj.thj.6200409","DOIUrl":null,"url":null,"abstract":"<p><p>Acute tumour lysis syndrome (TLS) is a very rare complication of cytotoxic therapy in patients with chronic lymphocytic leukaemia (CLL). We report a patient with CLL who developed tumour lysis syndrome twice after oral fludarabine therapy. Both times TLS developed more than 2 weeks after the initiation of therapy. To our knowledge this is the first reported case of TLS in CLL precipitated by oral fludarabine.</p>","PeriodicalId":22486,"journal":{"name":"The hematology journal : the official journal of the European Haematology Association","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/sj.thj.6200409","citationCount":"6","resultStr":"{\"title\":\"Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.\",\"authors\":\"Akila Ramachandran, Gautam Majumdar\",\"doi\":\"10.1038/sj.thj.6200409\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acute tumour lysis syndrome (TLS) is a very rare complication of cytotoxic therapy in patients with chronic lymphocytic leukaemia (CLL). We report a patient with CLL who developed tumour lysis syndrome twice after oral fludarabine therapy. Both times TLS developed more than 2 weeks after the initiation of therapy. To our knowledge this is the first reported case of TLS in CLL precipitated by oral fludarabine.</p>\",\"PeriodicalId\":22486,\"journal\":{\"name\":\"The hematology journal : the official journal of the European Haematology Association\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1038/sj.thj.6200409\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The hematology journal : the official journal of the European Haematology Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/sj.thj.6200409\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The hematology journal : the official journal of the European Haematology Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/sj.thj.6200409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.
Acute tumour lysis syndrome (TLS) is a very rare complication of cytotoxic therapy in patients with chronic lymphocytic leukaemia (CLL). We report a patient with CLL who developed tumour lysis syndrome twice after oral fludarabine therapy. Both times TLS developed more than 2 weeks after the initiation of therapy. To our knowledge this is the first reported case of TLS in CLL precipitated by oral fludarabine.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
